Robert A. Screaton, PhD's expertise is in cell signaling, metabolism and cell death. He uses functional genomics approaches to identify novel components of signal transduction pathways and then develop and analyze pre-clinical models to study their roles in vivo. His group has established a high-throughput, robotic cell-based screening facility at the Children’s Hospital of Eastern Ontario Research Institute (CHEO-RI) with microplate imaging capacity, designed specifically to enable genome wide RNAi and overexpression screens. They have collaborated with local, national and international researchers to perform cell-based screens focused on mitochondrial function, with outcomes designed to improve understanding of the etiologies and treatment of Parkinson’s disease, diabetes and cancer.